Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies a seven-long non-coding RNA (lncRNA) signature linked to RNA modification writers that predicts prognosis and immunotherapy response in lung adenocarcinoma (LUAD). The model aids in personalized LUAD treatment strategies.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Lung adenocarcinoma (LUAD) is a major non-small cell lung cancer (NSCLC) subtype.
- RNA adenosine modifications (m6A, m1A, APA, A-to-I editing) are crucial in tumor progression.
- The clinical role of RNA modification writer-associated long non-coding RNAs (lncRNAs) in LUAD is not well understood.
Purpose Of The Study
- To investigate the clinical significance of RNA modification writer-related lncRNAs in LUAD.
- To develop a prognostic signature based on these lncRNAs for LUAD patients.
- To evaluate the association of the signature with the tumor microenvironment and immunotherapy response.
Main Methods
- Utilized The Cancer Genome Atlas (TCGA) database for transcriptomic and clinical data.
- Employed univariate Cox, consensus clustering, and LASSO Cox regression to build prognostic signatures.
- Assessed immune infiltration and immunotherapy response using ESTIMATE, CIBERSORT, ssGSEA, and TIDE algorithms.
Main Results
- A seven-lncRNA prognostic signature associated with RNA modification writers was established.
- A high-risk group exhibited poorer prognosis, higher grade, increased tumor mutation burden (TMB), and distinct immune profiles.
- The high-risk group showed greater sensitivity to immunotherapy, indicated by lower TIDE scores.
Conclusions
- A novel seven-lncRNA prognostic model for LUAD was developed, reflecting prognosis, tumor microenvironment, and immunotherapy response.
- Specific lncRNAs (LINC01352, AC024075.1, AC005070.3, AL133445.2, AC005856.1, LINC00968) were downregulated, while AC092168.2 was upregulated in LUAD.
- This RNA modification writer-related lncRNA signature holds potential for guiding personalized LUAD therapies.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...